MétaCan
Menu
Back to cohort

PSP94: Evaluation of Prognostic Utility in Patients Treated with Radiotherapy for Nonmetastatic Prostate Cancer

2000· article· en· W1975423257 on OpenAlexaff
Glenn Bauman, Jim W. Xuan, Joseph L. Chin, Hiroshi Sakai, Yanbo Guo, Seema V. Garde, Jennifer E. Fraser, V.M. Venkatesan

Bibliographic record

VenueThe Prostate Journal · 2000
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsLondon Health Sciences Centre
Fundersnot available
KeywordsProstate cancerMedicineRadiation therapyInternal medicineProstateProstate-specific antigenOncologyUnivariate analysisCancerSubgroup analysisUrologyGastroenterologyConfidence intervalMultivariate analysis

Abstract

fetched live from OpenAlex

ABSTRACT Objectives: Conflicting reports exist as to the utility of PSP94 in the diagnosis and management of prostate cancer. We have identified serum‐bound forms of PSP94 in prostate cancer patients. To further evaluate the usefulness of this finding, we measured bound and free serum PSP94 levels in patients with nonmetastatic prostate cancer before radiotherapy. Materials and Methods: Pretreatment levels of free PSP94 in 42 patients were measured in serum via a competitive enzyme‐linked immunosorbent assay. Levels of bound PSP94 were measured by a semiquantitative assay after fractionation of total serum proteins by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis and Western blot analysis. Pretreatment levels of prostate specific antigen (PSA) were measured by a commercially available assay. Archival sera from 42 patients and a subgroup of 27 patients with “favorable” pretreatment PSA values (i.e., < 10 ng/ml) were statistically analyzed. Pretreatment levels of PSP94 (free and bound) and PSA, as well as tumor stage and grade, were correlated with treatment outcome (biochemical relapse‐free survival) postradiotherapy. Results: Pretreatment PSA and the ratio of bound to free PSP94 were significant predictors of relapse postradiotherapy on univariate analysis. An elevated ratio of bound to free PSP94 was a stronger predictor (p = 0.0074) of relapse postradiotherapy compared with PSA level (p = 0.070) in a subgroup of prostate cancer patients with “favorable” pretreatment PSA levels. Conclusions: The results presented here indicate that serum PSP94‐bound complexes must be considered in evaluating the clinical utility of PSP94 as a prostate cancer marker. A higher ratio of bound to free PSP94 may indicate worse outcome postradiotherapy. Differential testing of serum PSP94 has shown that it, in addition to PSA, may be of prognostic value for patients receiving radiotherapy for nonmetastatic prostate cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.319
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2000
Admission routes1
Has abstractyes

Explore more

Same venueThe Prostate JournalSame topicProstate Cancer Diagnosis and TreatmentFrench-language works237,207